CytoSorbents Corporation (CTSO)

[andy55q]

Potential catalysts:

1. Q4 2014 sales results and shareholder letter.
2. IDE approval.
3. Start of Pivotal US cardiac trial.
4. Announcement of a partner for the US cardiac study. They may go it alone, but a partner would be a big boost to ramp up sales and distribution quickly in the US if approved.
5. Marketing approval and start of sales in the 6 EU countries where Fresenius is their distribution partner. The contract with them states they must secure this approval within 6 months.
6. Announcement of a pediatric version of Cytosorb. There are hints to this in development on the Cytosorb Registry web site.
7. Results of the US Air Force study on the use of Cytosorb for Rhabdomyolysis.
8. Results of the EU cardiac studies. One should be wrapping up this month and other in April I believe.
9. Result of the EU dosing study. This has been going on for quite a long time. Hopefully results will be soon.
10. Announcement of the name of the top 4 cardiac company that is evaluating Cytosorb in France and a possible partnership. Rumor is that it may the Sorin Group.
11. Result of any of the other 40 + investigator initiated studies in the EU.
12. Licensing or possible partnership for the Hemodefend product.
13. Results of the ABLE study, hopefully supporting the need for a product like Hemodefend
14. Updates on other pipeline products: ContrastSorb, DrugSorb and BetaSorb
15. Update in the SBIR contract with the US army for burn treatment
16. Update on the DARPA contract

From Yahoo MB luvboats2003 •9 minutes ago